Monitor upcoming quarterly results for revenue traction from FemaSeed and enrollment updates for the FemBloc FINALE trial. The Cat III reimbursement effective Jan 2027 could be a catalyst for adoption, but no near-term revenue inflection is quantified.
Price Chart
Executive Summary
Femasys Inc. filed an 8-K on May 13, 2026, posting an updated corporate slide presentation (Exhibit 99.1) on its website for investor meetings. The presentation outlines the company's multi-asset women's health portfolio, including the FemaSeed fertility treatment and FemBloc permanent birth control device, and highlights recent milestones such as Cat III reimbursement for FemaSeed (effective Jan 2027) and ongoing enrollment in the FINALE pivotal trial for FemBloc. No new financial data or guidance was provided; the filing is a routine business update with no material quantitative changes.
Key Facts
- Femasys posted an updated corporate slide presentation on its website for investor meetings on May 13, 2026.
- The presentation highlights the FemaSeed fertility treatment and FemBloc non-surgical permanent birth control device.
- FemaSeed received Cat III reimbursement effective January 2027.
- FemBloc FINALE pivotal trial (Part B, n=523) is currently enrolling, initiated March 2026.
- No financial results, guidance, or material agreements were disclosed in the filing.
Financial Impact
No financial figures reported in the filing.
Risk Factors
- FemBloc remains in clinical trials with no guaranteed FDA approval timeline.
- No current revenue or profitability data disclosed; company is pre-revenue stage.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-021081 |
| Document: ef20073379_8k.htm | 0001140361-26-021081 |
| Document: 0001140361-26-021081-index-headers.html | 0001140361-26-021081 |
| Document: 0001140361-26-021081-index.html | 0001140361-26-021081 |
| Document: 0001140361-26-021081.txt | 0001140361-26-021081 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | Press Release | $1.67 | awaiting T+5 | — | $1.38 (−17.37%) |
Oct 15, 2026 11d ago | SC 13G | $1.74 $1.56 | ▼ −10.09% | ▼ −9.07% | $1.38 (−20.46%) |
Sep 29, 2026 27d ago | EFFECT | $2.09 $2.08 | ▲ +0.48% | ▲ +2.43% | $1.38 (+33.97%) |
Aug 14, 2026 10w ago | 8-K | $2.16 $2.98 | ▼ −37.96% | ▼ −39.15% | $1.38 (+36.11%) |
Aug 14, 2026 10w ago | Press Release | $2.16 $2.98 | ▲ +37.96% | ▲ +39.15% | $1.38 (−36.11%) |
Aug 11, 2026 10w ago | Insider Cluster | $2.35 $2.71 | ▲ +15.32% | ▲ +15.76% | $1.38 (−41.28%) |
Aug 7, 2026 11w ago | Press Release | $2.66 $2.29 | ▲ +13.91% | ▲ +14.31% | $1.38 (+48.12%) |
Jun 4, 2026 20w ago | 8-K | $7.14 $4.78 | ▼ −33.05% | ▼ −30.50% | $1.38 (−80.67%) |
May 13, 2026 23w ago | 8-K | $7.61 $6.75 | ▼ −11.38% | ▼ −10.66% | $1.38 (−81.87%) |
May 8, 2026 24w ago | 8-K | $8.08 $7.26 | ▼ −10.24% | ▼ −10.16% | $1.38 (−82.93%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers